Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Change in Acquisitions & Divestments (2021 - 2025)

Prime Medicine (PRME) has disclosed Change in Acquisitions & Divestments for 5 consecutive years, with $39.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 18.84% year-over-year to $39.1 million, compared with a TTM value of $95.8 million through Dec 2025, down 53.09%, and an annual FY2025 reading of $95.8 million, down 53.09% over the prior year.
  • Change in Acquisitions & Divestments was $39.1 million for Q4 2025 at Prime Medicine, down from $42.4 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $72.5 million in Q1 2024 and bottomed at $3.0 million in Q1 2025.
  • Average Change in Acquisitions & Divestments over 5 years is $31.7 million, with a median of $32.5 million recorded in 2022.
  • The sharpest move saw Change in Acquisitions & Divestments surged 233.68% in 2023, then crashed 95.86% in 2025.
  • Year by year, Change in Acquisitions & Divestments stood at $13.0 million in 2021, then surged by 92.31% to $25.0 million in 2022, then skyrocketed by 90.14% to $47.5 million in 2023, then tumbled by 30.79% to $32.9 million in 2024, then rose by 18.84% to $39.1 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for PRME at $39.1 million in Q4 2025, $42.4 million in Q3 2025, and $11.2 million in Q2 2025.